Women’s Health Therapeutics Market Expected To Trigger A Revenue Increase To USD 210.9 Billion By 2025:Key Participant Pfizer, Teva Pharmaceutical Industries Ltd

San Francisco, 23 October 2018 , The global Women’s Health Therapeutics Market size is expected to reach USD 210.9 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 8.8% over the forecast period. Entry of effective drugs, a rise in awareness about early diagnosis and treatment, along with prevalence of chronic diseases are among the key factors likely to drive the market during the forecast period.

The women’s health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications. In October 2016, Prelude Fertility, Inc. received USD 200 million from the Reproductive Biology Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing fertility services and treatment to people with delayed childbirth. Juneau Biosciences, LLC has deployed USD 35 million until 2017 towards development of molecular diagnostics and therapeutics for endometriosis (uterus) conditions.

In January 2018, Melinta Therapeutics, Inc. acquired The Medicines Company’s infectious diseases business. This acquisition would help to the former expand its portfolio by offering life-saving treatment options. In November 2017, Biocon launched KRABEVA, a biosimilar used for the treatment of metastatic colorectal, cervical, ovarian, and brain cancer. Increasing investments by top market players are anticipated to propel the global market over the forecast period.

There is significant unmet need associated with treatment options for female sexual dysfunction. Currently, there are no Food and Drug Administration (FDA)-approved drugs for the treatment of female sexual dysfunction and many promising molecules are in late stage of development phase. Some of these molecules include LibiGel by BioSante Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II of clinical trials respectively in U.S.

Full Research Report On Women’s Health Therapeutics Market Analysis:
www.grandviewresearch.com/industry-analysis/womens-health-therapeutics-market

Further key findings from the report suggest:

·         By type, infection accounted for the largest market share in 2017 and is expected to maintain its dominance during the forecast period due to rising drug approvals, availability of diagnostic tests and treatments, and high incidence of infectious diseases

·         Ovarian cancer is anticipated to be the fastest-growing sub-segment of oncology during the forecast period due to high prevalence of ovarian cancer and approval of new and improved drugs

·         North America is expected to maintain its dominance in the coming years due to high awareness about women’s health, increase in number of advanced diagnostic and treatment methods, mergers and acquisitions by market players, and rise in infections and cancer cases

·         Asia Pacific is likely to witness significant growth over the next decade due to improving healthcare facilities, increase in commercialization and approval of products, and investment by market players

·         Some of the key players in women’s health therapeutics market are Bayer AG, Merck & Co., Pfizer, Teva Pharmaceutical Industries Ltd, AstraZeneca, Bristol-Myers Squibb (BMS) Company, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and Sanofi.

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global women’s health therapeutics market based on type and region:

Women’s Health Therapeutics Type Outlook (Revenue, USD Million, 2014 - 2025)

·         Infection

·         Pregnancy

·         Oncology

o    Cervical Cancer

o    Ovarian Cancer

o    Uterine Cancer

o    Vaginal & Vulvar Cancer

Women’s Health Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    U.K.

o    France

o    Spain

o    Italy

·         Asia Pacific

o    China

o    Japan

o    India

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-womens-health-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Women’s Health Therapeuticss Market Is Poised To Reach USD 210.9 Billion By 2025:Key Participant Teva Pharmaceutical Industries Ltd

San Francisco, 04 October 2018, The global women’s health therapeutics market size is expected to reach USD 210.9 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 8.8% over the forecast period. Entry of effective drugs, a rise in awareness about early diagnosis and treatment, along with prevalence of chronic diseases are among the key factors likely to drive the market during the forecast period.

The women’s health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications. In October 2016, Prelude Fertility, Inc. received USD 200 million from the Reproductive Biology Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing fertility services and treatment to people with delayed childbirth. Juneau Biosciences, LLC has deployed USD 35 million until 2017 towards development of molecular diagnostics and therapeutics for endometriosis (uterus) conditions.

In January 2018, Melinta Therapeutics, Inc. acquired The Medicines Company’s infectious diseases business. This acquisition would help to the former expand its portfolio by offering life-saving treatment options. In November 2017, Biocon launched KRABEVA, a biosimilar used for the treatment of metastatic colorectal, cervical, ovarian, and brain cancer. Increasing investments by top market players are anticipated to propel the global market over the forecast period.

There is significant unmet need associated with treatment options for female sexual dysfunction. Currently, there are no Food and Drug Administration (FDA)-approved drugs for the treatment of female sexual dysfunction and many promising molecules are in late stage of development phase. Some of these molecules include LibiGel by BioSante Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II of clinical trials respectively in U.S.

Full Research Report On Women’s Health Therapeutics Market Analysis:
www.grandviewresearch.com/industry-analysis/womens-health-therapeutics-market

Further key findings from the report suggest:

·         By type, infection accounted for the largest market share in 2017 and is expected to maintain its dominance during the forecast period due to rising drug approvals, availability of diagnostic tests and treatments, and high incidence of infectious diseases

·         Ovarian cancer is anticipated to be the fastest-growing sub-segment of oncology during the forecast period due to high prevalence of ovarian cancer and approval of new and improved drugs

·         North America is expected to maintain its dominance in the coming years due to high awareness about women’s health, increase in number of advanced diagnostic and treatment methods, mergers and acquisitions by market players, and rise in infections and cancer cases

·         Asia Pacific is likely to witness significant growth over the next decade due to improving healthcare facilities, increase in commercialization and approval of products, and investment by market players

·         Some of the key players in women’s health therapeutics market are Bayer AG, Merck & Co., Pfizer, Teva Pharmaceutical Industries Ltd, AstraZeneca, Bristol-Myers Squibb (BMS) Company, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and Sanofi.

Browse More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global women’s health therapeutics market based on type and region:

Women’s Health Therapeutics Type Outlook (Revenue, USD Million, 2014 - 2025)

·         Infection

·         Pregnancy

·         Oncology

o    Cervical Cancer

o    Ovarian Cancer

o    Uterine Cancer

o    Vaginal & Vulvar Cancer

Women’s Health Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    U.K.

o    France

o    Spain

o    Italy

·         Asia Pacific

o    China

o    Japan

o    India

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-womens-health-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com

Hyperlipidemia Drugs Market Worth USD 22.6 Billion By 2022 | Key Industry Players AstraZeneca, Merck & Co., Inc.

San Francisco, 21 September 2018 , The global hyperlipidemiadrugs market size is expected reach USD 22.6 billion by 2022, according to a new report by Grand View Research, Inc., expanding at a CAGR of 2.3% during the forecast period. Several factors, such as increase in target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia, are stoking the growth of the market.

Hyperlipidemia is the most common type of dyslipidemia and is generally caused by abnormally high lipid levels in the blood. This condition can occur due to genetic factors (primary hyperlipidemia) as well as other factors such as poor diet and unhealthy lifestyle (secondary hyperlipidemia). Statins are the first line of treatment for secondary hyperlipidemia.

Target population of antihyperlipidemic drugs is broadly divided into statin users and nonstatin users. The revenue share of statin users has been declining. The nonstatin users segment consists of statin intolerant and nonresponsive population as well as familial hyperlipidemia (FH) population. Nonstatin users are seeking high-efficacy alternatives and this is anticipated to boost the revenue of this segment.

Upcoming patent expirations are expected to lead to greater genericization in the market, mostly among statins, cholesterol absorption inhibitors, and combination drugs. However, new product launches are anticipated to continue to drive the market. Several novel mechanisms of action such as ACL inhibition, DGAT2 inhibition, and anti-ANGPTL-3 are being investigated for their potential for treatment of hyperlipidemia as well as for reducing the risk of CVD.

Full Research Report On Hyperlipidemia Drugs Market Analysis:
www.grandviewresearch.com/industry-analysis/hyperlipidemia-drugs-market

Further key findings from the report suggest:

·         Statins dominated the drug classes in 2016 owing to their high usage as the first line of therapy

·         Recent launch of PCSK9 inhibitors, such as Repatha and Praluent, is likely to change the current therapeutic scenario due to their improved efficacy and safety profile

·         PCSK9 inhibitors are expected to displace existing expensive therapies, lomitapide, and mipomersen for the treatment of homozygous FH patients

·         Europe was the leading regional market in 2016. It is estimated to maintain its dominance till 2022 owing to high prevalence of hypercholesterolemia

·         There are fewer growth opportunities in Japan due to unavailability of key pipeline drugs such as bempedoic acid

·         AstraZeneca; Merck & Co., Inc.; Pfizer, Inc.; DAIICHI SANKYO COMPANY, LIMITED; Amgen, Inc.; and Sanofi are some of the key players operating in this market

·         Amgen, Inc.; Sanofi; and Esperion are expected to have the highest shares in this market by 2022

Browse More Reports Of This Category By Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global hyperlipidemia drugs market based on drug class and region:

Hyperlipidemia Drug Class Outlook (Revenue, USD Million, 2016 - 2022)

·         Statins

·         Bile Acid Sequestrants

·         Cholesterol Absorption Inhibitors

·         Fibric Acid Derivatives

·         PCSK9 Inhibitors

·         Combination

·         Miscellaneous

Hyperlipidemia Regional Outlook (Revenue, USD Million, 2016 - 2022)

·         U.S.

·         U.K.

·         Germany

·         Spain

·         France

·         Italy

·         Japan

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-hyperlipidemia-drugs-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com